TPR100-Rx utilises our skin delivery technology
TPR100-Rx will be a higher strength topical product available on prescription for the potential treatment of profound indications such as pain associated with osteoarthritis and will utilise our DermaSys® technology.
Futura has developed a highly efficient and proprietary delivery technology, DermaSys®, for the absorption of active molecules through the skin. The DermaSys® technology was originally developed for use in our topical treatment for erectile dysfunction, MED2002. DermaSys® is a versatile and bespoke technology in that it can be tailored to suit the specific active compound being used and the therapeutic indication. Such targeted delivery offers an optimised profile in terms of dose, onset time and duration of effect as well as an improved safety profile through lower systemic uptake and the reduced risk of side effects.
When we conducted the low dose in vitro and clinical permeation studies for TPR100 we also included within these studies a significantly higher dose of the same non-steroidal anti-inflammatory drug ("NSAID"). These studies gave positive results, showing an excellent dose-related response which offers us the potential to treat indications such as osteoarthritis pain that generally require a higher dose of NSAID to give an appropriate level of pain relief. TPR100-Rx, with its targeted delivery through the skin thanks to our DermaSys® technology, has the potential benefit of avoiding the systemic side-effects seen in the use of oral NSAIDs.
As this will be a prescription product, which is to an extent outside of our current area of expertise, we will appoint external consultants to assist us to progress TPR100-Rx commercially, which we believe represents a substantial market opportunity.